Mosaic Biosciences: Biologics Brief

Single B Cell Discovery: Platforms, Trade-offs, and How to Actually Choose

• Season 1 • Episode 2

Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.

0:00 | 52:43

Send us Fan Mail

Single B cell discovery has become one of the most powerful tools in antibody drug discovery, but with so many platforms on the market, how do you know which one is right for your campaign?

In this special Spotlight episode of The Biologics Brief, Mosaic Biosciences CSO Tracey Mullen sits down with Director of Antibody Discovery Christina Palmer to break down everything you need to know about single B cell discovery platforms, without the vendor spin.

What we cover:

  • What single B cell discovery is and why adoption has surged in recent years
  • The core trade-off between resolution and throughput, and why theoretical throughput numbers can be misleading
  • How to compare the major platform categories: high-content optofluidic screening (Beacon), microfluidic droplet systems, sequencing-first workflows, and FACS-based platforms
  • Why genotype-phenotype linkage matters more than most people realize
  • How AI is changing the way antibody candidates are prioritized
  • A practical 5-question framework for choosing the right single B cell workflow for your program

Whether you're a biotech team evaluating platforms for the first time or a seasoned drug discovery scientist looking to pressure-test your current approach, this episode gives you the tools to make a more informed decision.

About The Biologics Brief
The Biologics Brief is a podcast from Mosaic Biosciences, a biologics CRO specializing in antibody discovery and engineering. Each episode features conversations with scientists and industry experts on the topics that matter most in biologics drug development.


🎧 Listen now and subscribe wherever you get your podcasts.

mosaicbio.com